...
首页> 外文期刊>Cellular & molecular biology letters. >VEGF AND SEMA4D HAVE SYNERGISTIC EFFECTS ON THE PROMOTION OF ANGIOGENESIS IN EPITHELIAL OVARIAN CANCER
【24h】

VEGF AND SEMA4D HAVE SYNERGISTIC EFFECTS ON THE PROMOTION OF ANGIOGENESIS IN EPITHELIAL OVARIAN CANCER

机译:VEGF和SEMA4D对促进上皮性卵巢癌血管生成有协同作用

获取原文

摘要

Background: Anti-angiogenesis therapy that targets VEGF is one of the important treatment strategies in advanced ovarian cancer. However, depending on the pharmaceutical agent, treatment can have undesirable side effects. SEMA4D has recently gained interest for its role in promoting angiogenesis. Here, we try to further understand the mechanism by which SEMA4D promotes angiogenesis in ovarian cancer. Methods: Correlation and western blot assaya were used to detect the relationship between VEGF and SEMA4D in clinical tissues and cells. Vasculogenic mimicry and transwell migration analyses were used to detect the roles of VEGF, SEMA4D and plexin-B1 on vasculogenic mimicry and migration. Vascular density and SEMA4D expression was determined using immunofluorescence staining in clinical tissues of EOC. Western blot was used to detect the expressions of CD31, MMP2 and VE-cadherin. We also analyzed the relationship between VEGF-SEMA4D and malignant tumor prognosis. Results: We found that knockdown of VEGF could suppress SEMA4D expression and that the expressions of VEGF and SEMA4D have a positive correlation in EOC cancer tissues. Vasculogenic mimicry and transwell migration analyses showed that SEMA4D and VEGF have a synergistic effect on the promotion of angiogenesis in A2780 and HUVEC cells. Soluble SEMA4D (sSEMA4D) could promote VM and migration in A2780 and HUVEC cells via the SEMA4D/plexin-B1 pathway, but the effect was not noted in stably transfected shR-plexin-B1 cells. In clinical tissues of EOC, the vascular density and SEMA4D/plexin-B1 expression were higher. When VEGF, SEMA4D and plexin-B1 was knocked down, the expression of CD31, MMP2 and VE-cadherin, which are the markers and initiators of angiogenesis and the epithelial–mesenchymal transition (EMT) process were reduced. VEGF and SEMA4D had a positive correlation with the malignant degree of ovarian cancer, and SEMA4D can serve as an independent prognostic factor. Conclusions: VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer. Targeting VEGF and the SEMA4D signaling pathway could be important for the therapy for EOC.
机译:背景:靶向VEGF的抗血管生成疗法是晚期卵巢癌的重要治疗策略之一。但是,根据药剂的不同,治疗可能会产生不良的副作用。 SEMA4D最近因其在促进血管生成中的作用而受到关注。在这里,我们试图进一步了解SEMA4D促进卵巢癌血管生成的机制。方法:采用相关和蛋白质印迹法检测临床组织和细胞中VEGF与SEMA4D的关系。使用血管生成模拟和transwell迁移分析来检测VEGF,SEMA4D和plexin-B1在血管生成模拟和迁移中的作用。使用免疫荧光染色在EOC的临床组织中测定血管密度和SEMA4D表达。 Western blot检测CD31,MMP2和VE-cadherin的表达。我们还分析了VEGF-SEMA4D与恶性肿瘤预后的关系。结果:我们发现敲低VEGF可以抑制SEMA4D的表达,并且VEGF和SEMA4D的表达在EOC癌组织中呈正相关。血管生成模拟和transwell迁移分析表明,SEMA4D和VEGF对促进A2780和HUVEC细胞中的血管生成具有协同作用。可溶性SEMA4D(sSEMA4D)可以通过SEMA4D / plexin-B1途径促进A2780和HUVEC细胞中的VM和迁移,但在稳定转染的shR-plexin-B1细胞中未发现这种作用。在EOC的临床组织中,血管密度和SEMA4D / plexin-B1表达较高。当VEGF,SEMA4D和plexin-B1被敲低时,CD31,MMP2和VE-钙粘着蛋白的表达降低,它们是血管生成和上皮-间质转化(EMT)过程的标志物和引发剂。 VEGF和SEMA4D与卵巢癌的恶性程度呈正相关,SEMA4D可作为独立的预后因素。结论:VEGF和SEMA4D在促进上皮性卵巢癌血管生成中具有协同作用。靶向VEGF和SEMA4D信号通路可能对EOC的治疗很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号